COMPANY

Quoin Pharmaceuticals

HQ: Ashburn, VA source · quoinpharma.com ↗ · Southeast

Keywords: Netherton syndrome scleroderma peeling skin syndrome rare disease QRX003

Location: Ashburn, VA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Timeline

Aug 28, 2026 Raise Private placement: $30.8M (total, as published), announced Aug 28, 2026. Source: SEC filing. source ↗ · Form D filed Sep 10, 2026 SEC Form D ↗
Mar 19, 2026 Trial start 2: Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome source ↗
Oct 10, 2025 Raise Private placement: $16.5M (total, as published), announced Oct 10, 2025. Source: SEC filing. source ↗ · Form D filed Oct 23, 2025 SEC Form D ↗
Oct 6, 2025 Trial start Phase 2/Phase 3: Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome source ↗
Dec 20, 2024 Raise Follow-on offering: $6.8M (total, as published), announced Dec 20, 2024. Source: company release on GlobeNewswire. source ↗
Mar 14, 2023 Trial start Phase 2/Phase 3: Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome source ↗
Jun 23, 2022 Trial start Phase 2/Phase 3: Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome source ↗

Dec 30, 2026 (ESTIMATED) · Phase 2/Phase 3 · Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome · NCT06953466
Dec 30, 2026 (ESTIMATED) · Phase 2/Phase 3 · Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome · NCT05789056
Jan 31, 2027 (ESTIMATED) · 2 · Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome · NCT07538583

Estimated primary completion per ClinicalTrials.gov. Dates move.

Raised: $54.1M. Last 2 years.

Aug 28, 2026 Private placement: $30.8M (total, as published), announced Aug 28, 2026. Source: SEC filing. source ↗ · Form D filed Sep 10, 2026 SEC Form D ↗
Oct 10, 2025 Private placement: $16.5M (total, as published), announced Oct 10, 2025. Source: SEC filing. source ↗ · Form D filed Oct 23, 2025 SEC Form D ↗
Dec 20, 2024 Follow-on offering: $6.8M (total, as published), announced Dec 20, 2024. Source: company release on GlobeNewswire. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT07538583	Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome	2	Recruiting	Mar 19, 2026	Jan 31, 2027 (estimated)
NCT06953466	Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome	Phase 2/Phase 3	Recruiting	Oct 6, 2025	Dec 30, 2026 (estimated)
NCT05789056	Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome	Phase 2/Phase 3	Recruiting	Mar 14, 2023	Dec 30, 2026 (estimated)
NCT05521438	Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome	Phase 2/Phase 3	Active, not recruiting	Jun 23, 2022	Dec 30, 2025 (actual)

Form D raises come from the company’s own SEC filing (last 2 years).

2026-09-10 Raise Private raise (SEC Form D): $50.0M sold; issuer “Quoin Pharmaceuticals Ltd.”. Verified from the SEC filing. SEC filing ↗
2025-10-23 Raise Private raise (SEC Form D): $105.3M sold; issuer “Quoin Pharmaceuticals, Ltd.”. Verified from the SEC filing. SEC filing ↗